![]() ![]() Incidence of grade III/IV toxicities (at full ruxolitinib dosage). Rate of molecular remission (T-cell receptor clearance, STAT3 mutation clearance) at 4, 8, 12 months. Rate of conversion from PR at 4 months to CR at 8 and 12 months (at full ruxolitinib dosage). ![]() To determine the overall response rate (complete response and partial response ) of ruxolitinib in patients with T-LGLL. Determine the overall response rate (ORR) of ruxolitinib in patients with T-cell large granular lymphocytic leukemia (T-LGLL) as compared to historical controls. Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |